Oncotarget

Clinical Research Papers:

Plasma biomarkers of clinical response during chemotherapy plus combination antiretroviral therapy (cART) in HIV+ patients with advanced Kaposi sarcoma

Rosamaria Tedeschi _, Ettore Bidoli, Maria Teresa Bortolin, Ornella Schioppa, Emanuela Vaccher and Paolo De Paoli

PDF  |  HTML  |  How to cite

Oncotarget. 2015; 6:30334-30342. https://doi.org/10.18632/oncotarget.4571

Metrics: PDF 1774 views  |   HTML 1869 views  |   ?  


Abstract

Rosamaria Tedeschi1,*, Ettore Bidoli2,*, Maria Teresa Bortolin1, Ornella Schioppa3, Emanuela Vaccher3, Paolo De Paoli4

1Microbiology-Immunology and Virology Unit, Centro di Riferimento Oncologico, IRCCS, 33081 Aviano, Italy

2Epidemiology and Biostatistic Unit, Centro di Riferimento Oncologico, IRCCS, 33081 Aviano, Italy

3Medical Oncology A, Centro di Riferimento Oncologico, IRCCS, 33081 Aviano, Italy

4Scientific Directorate, Centro di Riferimento Oncologico, IRCCS, 33081 Aviano, Italy

*These authors have contributed equally to this work

Correspondence to:

Rosamaria Tedeschi, e-mail: [email protected]

Keywords: Kaposi sarcoma (KS), combination antiretroviral therapy (cART), G-CSF, HGF, endoglin

Received: April 17, 2015     Accepted: June 26, 2015     Published: July 09, 2015

ABSTRACT

This study aimed to evaluate plasma concentration of selected cancer-associated inflammatory and immune-modulated cytokines in HIV+ patients with advanced Kaposi sarcoma (KS), and to explore candidate biomarkers capable of predicting clinical outcome in response to chemotherapy (CT) plus combination antiretroviral therapy (cART).

Thirty-seven plasma cytokines/chemokines were assessed by Luminex technology in 27 consecutive HIV+ KS patients, followed-up during CT and cART of maintanence (m-cART). Associations between plasma concentration of biomarkers and patient clinical response to m-cART were evaluated by means of Hazard Ratios (HRs) and corresponding 95% Confidence Intervals (CIs).

Plasma baseline concentration of Granulocyte colony-stimulating factor (G-CSF), Hepatocyte growth factor (HGF) and endoglin were found to be associated with m-cART clinical response (HR:1.56, 95%CI:1.09–2.22, p = 0.01; HR:0.32, 95% CI:0.10–0.99, p = 0.05; HR:0.72, 95% CI:0.54–0.96, p = 0.03, respectively). The multivariate analysis confirmed the associations of baseline plasma G-CSF and HGF concentration with m-cART clinical complete remission response (HR:1.78, 95% CI:1.15–2.74, p = 0.009; HR:0.19, 95% CI:0.04–0.95, p = 0.04).

Our exploratory study suggested that plasma G-CSF, HGF and endoglin may be novel predictors of clinical response during m-cART in HIV+ KS patients. Nonetheless, these findings should be further validated in an independent population study.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4571